Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Asterand, a provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery research, has appointed Dalia Cohen as the new chief scientific officer of the company.
Subscribe to our email newsletter
Most recently, Cohen worked as the chief scientific officer in Rosetta Genomics, a developer of microRNA-based molecular diagnostics.
Asterand CEO Martyn Coombs said that Cohen has a reputation as an innovative scientist with an in-depth knowledge of drug discovery and development, oncology, personalised medicine and diagnostics.
Asterand CSO Dalia Cohen said that through the acquisition of BioSeek, Asterand has added the possibility of using sophisticated human primary cell based models and screening to predict at an early stage whether compounds will work in patients. She is eager to direct Asterand’s scientific strategy to maximise its growth potential over the long term.”